KING OF PRUSSIA, PA — SEED Therapeutics, Inc. will present early clinical and preclinical data for its experimental cancer therapy ST-01156 at the upcoming 2026 American Society of Clinical Oncology Annual Meeting, as the company advances a new class of molecular glue degraders into human testing for hard-to-treat solid tumors.
The company said the poster presentation will outline the design of an ongoing first-in-human Phase 1 trial evaluating ST-01156, an orally administered degrader targeting RNA-binding motif protein 39, or RBM39, in patients with advanced solid malignancies.
The study focuses on cancers believed to depend on RBM39 activity, a target that has drawn interest in oncology research but has faced limitations from earlier drug candidates tied to toxicity and pharmacologic constraints.
Clinical and medical lead Eric K. Rowinsky described RBM39 as “a compelling oncology target whose therapeutic potential has been constrained by prior chemical matter.”
Rowinsky added that ST-01156 “was designed as an oral, selective, brain-penetrant molecular glue degrader” intended to evaluate whether the target can be addressed with a pharmacologic profile suitable for patients with advanced solid tumors.
He further noted that the Phase 1 study is designed to “rigorously characterize its safety, pharmacology, and early signals of activity in patients with RBM39-dependent cancers, including those who have exhausted standard treatment options.”
SEED described ST-01156 as a selective therapy engineered to degrade RBM39 proteins while potentially improving tolerability and tissue penetration compared with earlier approaches.
The presentation is scheduled for May 30 during the Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology session at McCormick Place in Chicago.
The abstract, titled “First-in-Human Clinical Evaluation of ST-01156, an Optimized and Selective Degrader of RNA-Binding Motif 39 (RBM39),” includes investigators from several cancer research institutions and centers specializing in experimental oncology therapies.
Molecular glue degraders have emerged as an increasingly competitive area in biotechnology and pharmaceutical development, as drugmakers seek to target proteins previously considered difficult or impossible to treat with conventional small molecules. Early-stage oncology programs focused on selective protein degradation have attracted growing investment amid demand for new therapies in resistant and metastatic cancers.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.